DERMATA THERAPEUTICS INC (DRMA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.76-10.87%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · DRMA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
DRMA — litigation filed
Dated 2026-10-29
Other Events. On October 29, 2027, Dermata Therapeutics, Inc. (the “Company”) issued a press release announcing enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment, the Company’s once-weekly acne treatment, in participants with acne. The Company expects to launch this second commercial product in the first half of 2027 . Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Secu…
Why it matters: Dermata used $4.9 million in operating cash in the first half. Lower cash use would ease pressure to raise more funds.
Supportive ifThe November 13 report shows Q3 operating cash use below $2.45 million. That is half the first-half total per quarter.
Worry ifThe November 13 report shows Q3 operating cash use at or above $2.45 million.
Why it matters: Full cash exercise could add about $6.7 million. The release says the company cannot be sure investors will exercise them.
Watch forStockholders approve the warrant shares and holders exercise Series E or F warrants for cash.
Also watch forStockholders do not approve the warrant shares, or no warrants are exercised for cash.
Why it matters: At June 30, cash was $4.4 million, and management said it would fund operations into Q4 2026. More financing may dilute shareholders.
Worry ifBy the November 13 earnings update, cash is below $4.4 million. Management reports a new equity raise or less time before cash runs out.
Less concerning ifThe November 13 update shows cash above $4.4 million, no new equity raise, and runway beyond Q4 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$286 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $1,064 loss on $10,000 · 10.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,943 loss on $10,000 · 79.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.